Hangzhou HealSun Biopharm Co., Ltd. announced that it has raised CNY 200 million in a round of funding led by new investors, Shenzhen Kangzhe Pharmaceutical Co., Ltd. and China Medical System Holdings Limited on October 7, 2023. The transaction also included participation from returning investor, Hangzhou Oriental Jiafu Asset Management Co., Ltd.